Guangzhou Institute of Respiratory Disease (Responsible Party)
Guangzhou Institute of Respiratory Disease (Responsible Party)
Guangzhou, Guangzhou, China1 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC | Small Cell Lung Cancer Extensive Stage | Recruiting | Phase 2 | 2024-12-18 | NCT06739928 |